arization surgery, and surgical ablation products. The following are the principal products offered by the CSH division: Transcatheter Heart Valves (TCVs): The company’s latest generation TCVs include the CoreValve family of aortic valves. CoreValve, which is the only TCV system shown to be superior to open-heart surgery, has received the U.S. FDA approval for extreme and high risk patients. Percutaneous Coronary Intervention (PCI): The company’s latest generation PCI stent products include its Resolute Integrity drug-eluting stent systems, which have received the U.S. FDA approval, as well as Resolute Onyx drug-eluting stent systems, which have received CE Mark approval. Heart Surgery: The company offers a complete line of surgical valve replacement and repair products for damaged or diseased heart valves. The company’s replacement products include both tissue and mechanical valves. The company also offers a line of blood-handling products that form a circulatory support system to maintain and monitor blood circulation and coagulation status, oxygen supply, and body temperature during arrested heart surgery. Additionally, the company offers surgical ablation systems and positioning and stabilization technologies. Aortic and Peripheral Vascular Disease Management (APV) The company’s APV division is comprised of a line of products and therapies to treat aortic disease (such as aneurysms, dissections, and transections), as well as peripheral vascular disease (PVD), and critical limb ischemia (CLI). Its products include endovascular stent graft systems, peripheral drug coated balloon, stent and angioplasty systems, and carotid embolic protection systems for the treatment of vascular disease outside the heart, as well as products for superficial and deep venous disease. The following are the principal products offered by its APV division: Endovascular Stent Grafts: The company’s products are designed to treat aortic aneurysms in either the abdomen (AAA) or thoracic (TAA) regions of the aorta. The company’s product line includes a range of endovascular stent grafts and accessories, including Endurant 2S Abdominal Aortic Aneurysm (AAA) Stent Graft System and the Valiant Captivia Thoracic Aortic Aneurysm (TAA) stent graft system and the Aptus endo anchors. Peripheral Vascular Intervention (PVI): The company’s primary PVI products include percutaneous angioplasty balloons, including the IN.PACT family of drug-coated balloons, which have the U.S. FDA and CE Mark approval, as well as peripheral stents, such as the Protege & Complete Self Expanding Vascular Stents, the Visi-Pro and Assurant Cobalt Balloon Expandable stents and directional atherectomy products, such as the TurboHawk plaque excision system, and other procedure support products. EndoVenous (EV): The company’s EndoVenous product lines are used to treat superficial and deep venous diseases in the lower extremities and include the Closure Fast RF ablation system, the VenaSeal medical adhesive system and also focusing on embolisms with the Concerto detachable coil system, Micro Vascular Plug (MVP), the PV ONYX liquid embolic system and other procedure support products. Customers The primary medical specialists who use the Cardiac and Vascular products include electrophysiologists, implanting cardiologists, heart failure specialists, cardiovascular, cardiothorasic, and vascular surgeons and interventional cardiologists and radiologists. Competition The company’s primary competitors are St. Jude Medical, Inc. (St. Jude); Boston Scientific Corporation (Boston Scientific); Sorin Group (Sorin); Edwards Lifesciences Corporation (Edwards); C.R. Bard Inc. (Bard); and Abbott Laboratories (Abbott). Minimally Invasive Therapies Group Surgical Solutions Surgical Solutions develops, manufactures, and markets surgical, general surgical, and hernia products and therapies to treat diseases and conditions that are typically, but not exclusively, addressed by surgeons. In addition, it develops, manufactures, and markets various products in the fields of minimally invasive gastrointestinal diagnostics, ablation, and interventional lung. The fol
medtronic plc (MDT:New York)
20 On Hatch
Lower Hatch Street
Phone: 353 1 438 1700
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|No competitor information is available for MDT.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact MEDTRONIC PLC, please visit www.medtronic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.